EUVIMEDDescoperă EUVIMED
Crossref

Transcatheter aortic valve implantation for severe aortic regurgitation using the J‐Valve system: A midterm follow‐up study

Min Jin, Haitao Zhang, Qing Zhou, Shuchun Li, Dongjin Wang iD

Catheterization and Cardiovascular Interventions · 2024

DOI: 10.1002/ccd.31196 ↗

At a glance

Journal article in Catheterization and Cardiovascular Interventions, 2024. Written by Min Jin and 4 co-authors. Institution: Department of Cardiac Surgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China. Major MEDLINE topics: Aortic Valve Insufficiency, Transcatheter Aortic Valve Replacement, Heart Valve Prosthesis, Prosthesis Design. Cited 2 times so far (Crossref); 18 references. Funded by: Healthy Science and Technological Development Foundation of Nanjing, National Natural Science Foundation of China, The Clinical Medical Center of Nanjing Cardiovascular Diseases.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Background

Transcatheter aortic valve implantation (TAVI) is a well‐established intervention for severe aortic valve stenosis. However, its application for severe aortic regurgitation (AR) is still under evaluation. This study aims to present the 3‐year follow‐up outcomes of the J‐Valve system in managing severe AR.

Aims

The aim of this study was to evaluate the mid‐term efficacy and durability of the J‐Valve system in the treatment of severe AR and to provide new information on this intervention.

Methods

In this retrospective, single‐center study, we evaluated the prognostic outcomes of patients with AR, who underwent treatment with the J‐Valve system at Nanjing Drum Tower Hospital. Consecutive patients who were treated with the J‐Valve were included in the analysis. The study focused on the echocardiographic follow‐up to assess the effectiveness and durability of the J‐Valve system in managing AR.

Results

From January 2018 to December 2022, 36 high‐risk AR patients treated with the J‐Valve system had a procedural success rate of 97.2%, with one case requiring open‐heart surgery due to valve displacement. Significant improvements were observed in left ventricular diameter (from 63.50 [58.75–69.50] mm to 56.50 [53.00–60.50] mm, p < 0.001) and left atrial diameter (from 44.00 [40.00–45.25] mm to 39.00 [36.75–41.00] mm, p = 0.003) postsurgery. All patients completed the 1‐year follow‐up, with an overall mortality rate of 2 out of 36 (5.6%). Among the surviving patients, there was one case of III° atrioventricular block and one case of stroke, both occurring within 90 days postsurgery. After a 3‐year follow‐up, 15.0% of patients had mild or moderate valvular regurgitation, with no cases of moderate or severe paravalvular leak. Additionally, 89.5% of patients were classified as New York Heart Association class I or II, showing significantly enhanced cardiac function.

Conclusion

The J‐Valve system has shown positive therapeutic outcomes in treating AR, with notable effectiveness in managing the condition and significant improvements in heart failure symptoms and cardiac remodeling. However, due to the limited sample size and partial follow‐up data, it is important to emphasize the need for further research with comprehensive long‐term follow‐up, to fully validate these results.

Subjects

MeSH terms (MEDLINE)

Aortic Valve InsufficiencyTranscatheter Aortic Valve ReplacementHeart Valve ProsthesisProsthesis DesignRecovery of FunctionSeverity of Illness IndexAortic ValveHumansMaleRetrospective StudiesFemaleTime FactorsTreatment OutcomeAgedAged, 80 and overRisk FactorsFollow-Up StudiesHemodynamicsChinaVentricular Function, Left

Author keywords

J‐ Valve systemTAVIaortic regurgitation

Authors and institutions

  • Department of Cardiac Surgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China.
  • Department of Cardiac Surgery, Nanjing Drum Tower Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Graduate School of Peking Union Medical College, Nanjing, China.
  • Department of Cardiac Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.

ORCID profiles: Dongjin Wang

Funding

  • Healthy Science and Technological Development Foundation of Nanjing
  • National Natural Science Foundation of China
  • The Clinical Medical Center of Nanjing Cardiovascular Diseases

Cite

APA

Jin, M., Zhang, H., Zhou, Q., Li, S., & Wang, D. (2024). Transcatheter aortic valve implantation for severe aortic regurgitation using the J‐Valve system: A midterm follow‐up study. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31196

Vancouver

Jin M, Zhang H, Zhou Q, Li S, Wang D. Transcatheter aortic valve implantation for severe aortic regurgitation using the J‐Valve system: A midterm follow‐up study. Catheterization and Cardiovascular Interventions. 2024. doi:10.1002/ccd.31196

BibTeX
@article{Jin2024,
  author = {Jin, Min and Zhang, Haitao and Zhou, Qing and Li, Shuchun and Wang, Dongjin},
  title = {Transcatheter aortic valve implantation for severe aortic regurgitation using the J‐Valve system: A midterm follow‐up study},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2024},
  doi = {10.1002/ccd.31196}
}
Start for free →